Subsequent-generation sequencing reveals a novel pathogenic variant within the ATMgene
Introduction: Ataxia telangiectasia (A-T) is a unusual autosomal recessive multisystemic sickness. Victims with the A-T syndrome present a broad spectrum of sickness phenotypes. The ATM (ataxia telangiectasia mutated) gene, the one causative gene for A-T.
Methodology: A affected particular person of Persian origin presenting with typical A-T was referred to our genetics center for specialised genetic counseling and testing. Centered next-generation sequencing (NGS) was utilized. Sanger sequencing was used to substantiate the candidate variant. Modeling was carried out using the SWISS-MODEL server.Outcomes: A homozygous stop-gain variant c.829G > T (p.E277*) was found inside the ATM gene. This variant was confirmed by Sanger sequencing and modeling of native development and truncated development was carried out.
Conclusion: So far, only some pathogenic variants of the ATM gene have been reported from the Iranian inhabitants. The discovering has implications in molecular diagnostic for A-T in Iran.
geno-type
) Carbol Fuchsin (ZN,Strong) |
|
S005-125ML |
EWC Diagnostics |
1 unit |
EUR 3.16 |
|
Description: Carbol Fuchsin (ZN,Strong) |
Carbol Fuchsin (ZN,Strong) |
|
S005-500ML |
EWC Diagnostics |
1 unit |
EUR 10.92 |
|
Description: Carbol Fuchsin (ZN,Strong) |
) RIPA Lysis Buffer (Strong) |
|
abx090624-100l |
Abbexa |
100 µl |
EUR 150 |
RIPA Lysis Buffer (Strong) |
|
abx090624-1ml |
Abbexa |
1 ml |
Ask for price |
RIPA Lysis Buffer (Strong) |
|
abx090624-200l |
Abbexa |
200 µl |
Ask for price |
RIPA Lysis Buffer (Strong) |
|
MBS355478-100mL |
MyBiosource |
100mL |
EUR 210 |
RIPA Lysis Buffer (Strong) |
|
MBS355478-5x100mL |
MyBiosource |
5x100mL |
EUR 640 |
) Clear Seal Strong Sheet (100) |
|
MAAB-0685 |
Westburg |
each |
EUR 255.61 |
) HiDecal (Strong decalcifying solution) |
|
R085-500ML |
EWC Diagnostics |
1 unit |
EUR 21.95 |
|
Description: HiDecal (Strong decalcifying solution) |
) Tissue/cell lysis buffer（Strong) |
|
RM17482 |
Abclonal |
10mL |
EUR 53.14 |
 Medium) Modified Duncan Strong (DS) Medium |
|
M1237-500G |
EWC Diagnostics |
1 unit |
EUR 80.55 |
|
Description: Modified Duncan Strong (DS) Medium |
 HiVeg Medium) Modified Duncan Strong (DS) HiVeg Medium |
|
MV1237-500G |
EWC Diagnostics |
1 unit |
EUR 80.55 |
|
Description: Modified Duncan Strong (DS) HiVeg Medium |
) anti PAI-1 (very strong for human) |
|
MBS480230-1mg |
MyBiosource |
1mg |
EUR 790 |
anti PAI-1 (very strong for human) |
|
MBS480230-5x1mg |
MyBiosource |
5x1mg |
EUR 3315 |
) Silver Protein for Histology, Strong (not certified) |
|
25108-25 |
Polysciences Europe GmbH |
25g |
EUR 431 |
|
Description: 9015-51-4 |
 Magnetic Base Support Z w/ Strong Magnet - 34.5mm |
|
M-R-1013161 |
MiTeGen |
1 UNIT |
EUR 46 |
|
Description: Magnetic Base Support Z w/ Strong Magnet - 34.5mm |
 Magnetic Base Support Z w/ Strong Magnet - 27.5mm |
|
M-R-1015229 |
MiTeGen |
1 UNIT |
EUR 46 |
|
Description: Magnetic Base Support Z w/ Strong Magnet - 27.5mm |
 Seralite SRC-120, Strong Acid Cation Exchange Resin |
|
14891 |
Sisco Laboratories |
500 Gms |
EUR 3.76 |
|
|
|
Description: Part A |
 Seralite SRA-400, Strong Basic Anion Exchange Resin |
|
52228 |
Sisco Laboratories |
500 Gms |
EUR 5.82 |
|
|
|
Description: Part A |
 DiagAg™ Strong Anion Exchange Agarose Particles, 40 μm |
|
DAG-CL23-08 |
Creative Diagnostics |
25 mL |
EUR 1150 |
 A510, Type 2 Macroporous Strong Base Resin, Chloride Form |
|
50223-250 |
Polysciences Europe GmbH |
250ml |
EUR 47 |
|
Description: 69011-15-0 |
 Genistin |
|
N1860-20 |
ApexBio |
20 mg |
EUR 100 |
|
|
|
Description: TdT inhibitor |
Genistin |
|
abx282781-100g |
Abbexa |
100 µg |
Ask for price |
Genistin |
|
abx282781-20g |
Abbexa |
20 µg |
EUR 106.25 |
Genistin |
|
abx282781-50g |
Abbexa |
50 µg |
EUR 250 |
Genistin |
|
TB0370-1000 |
ChemNorm |
4X20mg |
EUR 321.6 |
Genistin |
|
MBS6086497-5x100mg |
MyBiosource |
5x100(mg |
EUR 1560 |
Genistin |
|
MBS3608735-5x200mg |
MyBiosource |
5x200mg |
EUR 930 |
 A400, Type 1 Porous Strong Base Anion Resin, Chorlide Form |
|
50218-1 |
Polysciences Europe GmbH |
1000ml |
EUR 144 |
|
Description: 9052-45-3 |
A400, Type 1 Porous Strong Base Anion Resin, Chorlide Form |
|
50218-250 |
Polysciences Europe GmbH |
250ml |
EUR 47 |
|
Description: 9052-45-3 |
 Genistin, >99% |
|
BC034-025 |
GenDepot |
25mg |
EUR 278.4 |
Genistin, >99% |
|
BC034-050 |
GenDepot |
50mg |
EUR 327.6 |
Genistin, >99% |
|
BC034-100 |
GenDepot |
100mg |
EUR 537.6 |
) Genistin(Genistoside) |
|
E1KS2301 |
EnoGene |
25mg |
EUR 211.2 |
) Genistin (Genistoside) |
|
MBS8506424-25mg |
MyBiosource |
25mg |
EUR 290 |
Genistin (Genistoside) |
|
MBS8506424-5x25mg |
MyBiosource |
5x25mg |
EUR 1150 |
Genistin (Genistoside) |
|
MBS384753-100mg |
MyBiosource |
100mg |
EUR 190 |
Genistin (Genistoside) |
|
MBS384753-25mg |
MyBiosource |
25mg |
EUR 140 |
Genistin (Genistoside) |
|
MBS384753-50mg |
MyBiosource |
50mg |
EUR 160 |
Genistin (Genistoside) |
|
MBS384753-5x100mg |
MyBiosource |
5x100mg |
EUR 855 |
 Genistin malonate |
|
TB0588-0005 |
ChemNorm |
10mg |
EUR 886.8 |
 Optically clear sealing film for qPCR, Strong Bond, for PP plates, 100/pk |
|
MS1000-PCR2 |
Benchmark Scientific |
1 each |
EUR 149.35 |
 DiagAg™ Phenyl Agarose Strong Hydrophobic Medium, 6% Crosslinked, 24-45 µm |
|
DAG-YS23-27 |
Creative Diagnostics |
25 mL |
EUR 850 |
 DiagAg™ Phenyl Agarose Strong Hydrophobic Medium, 6% Crosslinked, 45-165 µm, Low Capacity |
|
DAG-YS23-28 |
Creative Diagnostics |
25 mL |
EUR 850 |
 DiagAg™ Phenyl Agarose Strong Hydrophobic Medium, 6% Crosslinked, 45-165 µm, High Capacity |
|
DAG-YS23-29 |
Creative Diagnostics |
25 mL |
EUR 850 |
 and DMSO, for PP plates, 100/pk) Foil seals, strong bonding for cold storage (-200 to 110°C) and DMSO, for PP plates, 100/pk |
|
MS1000-F2 |
Benchmark Scientific |
1 each |
EUR 149.35 |
 IHC control with strong, moderate, low/negative expressersHumanBreastBreastIHC control) Estrogen receptor (ER) IHC control with strong, moderate, low/negative expressersHumanBreastBreastIHC control |
|
ERC083 |
Pantomics |
1.5mm |
EUR 50 |
 genesig Easy kit for Strongylus vulgaris |
|
Z-Path-S.vulgaris-EASY |
Novacyt Group |
50 tests |
EUR 410 |
|
Description: S.vulgaris |
 Strongyloides ELISA Kit |
|
MBS495518-5x96Tests |
MyBiosource |
5x96Tests |
EUR 2380 |
Strongyloides ELISA Kit |
|
MBS495518-96Tests |
MyBiosource |
96Tests |
EUR 520 |
 (HRP)) Strongzyme Goat anti Mouse IgG (H+L) (HRP) |
|
43R-1653 |
Fitzgerald |
1 ml |
EUR 763.2 |
|
Description: Strongzyme Goat anti-Mouse IgG (H+L) secondary antibody (HRP) |
 (HRP)) Strongzyme Rabbit anti Goat IgG (H+L) (HRP) |
|
43R-1650 |
Fitzgerald |
1 ml |
EUR 813 |
|
|
|
Description: Strongzyme Rabbit anti Goat IgG (H + L) (HRP) secondary antibody |
 (HRP)) Strongzyme Goat anti Rabbit IgG (H + L) (HRP) |
|
43R-1652 |
Fitzgerald |
1 ml |
EUR 648 |
|
|
|
Description: Strongzyme Goat anti Rabbit IgG (H + L) secondary antibody (HRP) |
 genesig Real-time PCR detection kit for Strongylus vulgaris |
|
Z-Path-S-vulgaris |
Novacyt Group |
150 tests |
EUR 808 |
|
Description: S.vulgaris |
 genesig Std Real-time PCR detection kit, Strongylus vulgaris |
|
Z-Path-S-vulgaris-std |
Novacyt Group |
150 tests |
EUR 602 |
|
|
|
Description: S.vulgaris |
 ELISA Kit (Human) (OKNA00174)) Strongyloides (IgG/IgM) ELISA Kit (Human) (OKNA00174) |
|
OKNA00174 |
Aviva Systems Biology |
96 Wells |
EUR 505.2 |
|
Description: Description of target: Strongyloides is a genus containing some 50 species of obligate gastrointestinal parasites of vertebrates. Strongyloides stercoralis is the scientific name of a human parasitic roundworm causing the disease of strongyloidiasis. Its common name is pinworm in the UK and threadworm in the US. The Strongyloides stercoralis nematode can parasitize humans. The adult parasitic stage lives in tunnels in the mucosa of the small intestine.S. stercoralis can be found in areas with tropical and subtropical climates but cases also occur in temperate area, more frequently in rural areas. S. stercoralis has a very low prevalence in societies where fecal contamination of soil or water is rare. Many people infected are usually asymptomatic at first. Symptoms include dermatitis: swelling, itching, larva currens, and mild hemorrhage at the site where the skin has been penetrated. If the parasite reaches the lungs, the chest may feel as if it is burning, and wheezing and coughing may result, along with pneumonia-like symptoms (Löffler's syndrome). The intestines could eventually be invaded, leading to burning pain, tissue damage, sepsis, and ulcers. In severe cases, edema may result in obstruction of the intestinal tract, as well as loss of peristaltic contractions. Strongyloides infection in immunocompromised individuals (particularly following the administration of steroids, for example following transplant surgery) can result in disseminated strongyloidiasis, in which worms move beyond the confines of the gut into other organs. This is fatal unless antiStrongyloides therapy is given.Locating juvenile larvae, either rhabditiform or filariform, in recent stool samples will confirm the presence of this parasite. Other techniques used include direct fecal smears, culturing fecal samples on agar plates, serodiagnosis through ELISA, and duodenal fumigation.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Reverse Capture Sandwich ELISA ;Sensitivity: Sensitivity is determined as the probability of the assay indicating a positive score in samples with the specific analyte present: 87.9% |
) StrongZyme Streptavidin-PolyHRP (High Load) |
|
43R-1645 |
Fitzgerald |
1 mg |
EUR 380 |
|
|
|
Description: StrongZyme Streptavidin-PolyHRP conjugate (High Load) |
 ELISA Kit) Rat Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392751-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Rat Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392751-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Rat Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392751-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Rat Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392751-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 ELISA Kit) Mouse Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392747-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Mouse Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392747-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Mouse Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392747-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Mouse Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392747-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 Recombinant Strongylocentrotus purpuratus Bindin |
|
MBS1128565-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1120 |
Recombinant Strongylocentrotus purpuratus Bindin |
|
MBS1128565-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 745 |
Recombinant Strongylocentrotus purpuratus Bindin |
|
MBS1128565-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 910 |
Recombinant Strongylocentrotus purpuratus Bindin |
|
MBS1128565-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 895 |
Recombinant Strongylocentrotus purpuratus Bindin |
|
MBS1128565-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 1065 |
 Recombinant Strongylocentrotus purpuratus Univin |
|
MBS1241085-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1045 |
Recombinant Strongylocentrotus purpuratus Univin |
|
MBS1241085-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 625 |
Recombinant Strongylocentrotus purpuratus Univin |
|
MBS1241085-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 800 |
Recombinant Strongylocentrotus purpuratus Univin |
|
MBS1241085-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 725 |
Recombinant Strongylocentrotus purpuratus Univin |
|
MBS1241085-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 935 |
 Recombinant Strongylocentrotus purpuratus Histone H4 |
|
MBS1043420-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1025 |
Recombinant Strongylocentrotus purpuratus Histone H4 |
|
MBS1043420-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 600 |
Recombinant Strongylocentrotus purpuratus Histone H4 |
|
MBS1043420-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 780 |
Recombinant Strongylocentrotus purpuratus Histone H4 |
|
MBS1043420-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 695 |
Recombinant Strongylocentrotus purpuratus Histone H4 |
|
MBS1043420-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 910 |
 Recombinant Strongylocentrotus purpuratus Profilin |
|
MBS1143303-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1065 |
Recombinant Strongylocentrotus purpuratus Profilin |
|
MBS1143303-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 650 |
Recombinant Strongylocentrotus purpuratus Profilin |
|
MBS1143303-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 815 |
Recombinant Strongylocentrotus purpuratus Profilin |
|
MBS1143303-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 750 |
Recombinant Strongylocentrotus purpuratus Profilin |
|
MBS1143303-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 955 |
 Recombinant Strongylocentrotus franciscanus Bindin |
|
MBS1245544-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1120 |
Recombinant Strongylocentrotus franciscanus Bindin |
|
MBS1245544-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 745 |
Recombinant Strongylocentrotus franciscanus Bindin |
|
MBS1245544-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 910 |
Recombinant Strongylocentrotus franciscanus Bindin |
|
MBS1245544-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 895 |
Recombinant Strongylocentrotus franciscanus Bindin |
|
MBS1245544-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 1065 |
 Recombinant Strongylocentrotus purpuratus Tektin-B1 |
|
MBS1372801-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1270 |
Recombinant Strongylocentrotus purpuratus Tektin-B1 |
|
MBS1372801-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 945 |
Recombinant Strongylocentrotus purpuratus Tektin-B1 |
|
MBS1372801-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 1065 |
Recombinant Strongylocentrotus purpuratus Tektin-B1 |
|
MBS1372801-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 1135 |
Recombinant Strongylocentrotus purpuratus Tektin-B1 |
|
MBS1372801-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 1210 |
 Recombinant Strongylocentrotus purpuratus Late histone H2B.L1 |
|
MBS1210922-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1045 |
Recombinant Strongylocentrotus purpuratus Late histone H2B.L1 |
|
MBS1210922-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 625 |
Recombinant Strongylocentrotus purpuratus Late histone H2B.L1 |
|
MBS1210922-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 800 |
Recombinant Strongylocentrotus purpuratus Late histone H2B.L1 |
|
MBS1210922-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 725 |
Recombinant Strongylocentrotus purpuratus Late histone H2B.L1 |
|
MBS1210922-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 935 |
 Recombinant Strongylocentrotus purpuratus Late histone H2A.L3 |
|
MBS1196903-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1045 |
Recombinant Strongylocentrotus purpuratus Late histone H2A.L3 |
|
MBS1196903-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 625 |
Recombinant Strongylocentrotus purpuratus Late histone H2A.L3 |
|
MBS1196903-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 800 |
Recombinant Strongylocentrotus purpuratus Late histone H2A.L3 |
|
MBS1196903-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 730 |
Familial dilated cardiomyopathy introduced on by a novel variant inside the Lamin A/C gene: a case report
Background: Familial dilated cardiomyopathy (FDCM) is generally inherited as an autosomal dominant trait. The Lamin A/C (LMNA) gene variants have been acknowledged to be associated to DCM, conductive system issues, sort 2 Emery-Dreifuss muscular dystrophy and a lot of different totally different issues. Proper right here, we reported a novel variant inside the LMNA gene that’s prone to be related to FDCM.
Case presentation: A 30-year-old youthful man was hospitalized for chest tightness, extreme fatigue, palpitation and impaired train tolerance. He had scientific traits along with cardiac dilatation, atrial tachyarrhythmia, excessive conductive system issues, and dyskinesia of every greater limbs and the neck. Genetic sequence analysis indicated that the affected particular person carried a novel c.1325 T>C heterozygous LMNA gene variant. Catheter ablation and cardiac resynchronization treatment with pacing carry out (CRT-P) have been carried out to cope with the arrhythmia.
Conclusion: The variant c.1325 T>C is a novel variant inside the LMNA gene that has not been beforehand reported. Youthful victims with DCM, conductive system issues and skeletal myopathy must be alert to the potential for LMNA gene variant. Cardiac resynchronization treatment (CRT) may be an reasonably priced choice for affected particular person carrying a LMNA gene variant with third-degree atrioventricular block even when the left ventricular ejection fraction is preserved with the intention to cease the deterioration of cardiac carry out introduced on by correct ventricular pacing dependency.
Genetic analysis of youngsters with congenital ocular anomalies in three ecological areas of Nepal: a piece II of Nepal pediatric ocular sicknesses analysis
Background: Genetic eye sicknesses characterize a giant and heterogeneous group of childhood ocular morbidity. Explicit particular person sicknesses might set off a lot of structural anomalies and developmental choices. Nepal Pediatric Ocular Sickness Analysis (NPODS) was a population-based epidemiological analysis carried out all through three ecological areas of Nepal to search out out the prevalence and etiology of childhood ocular morbidity and blindness. In Half II of this analysis, genetic analysis was carried out for youths who’ve been found to have congenital ocular anomalies.
Methodology: It was a cross sectional descriptive analysis. A whole of 10,270 children all through three completely totally different ecological areas in Nepal (Low lands, hills, and mountains) underwent ocular examinations in NPODS. Out of 374 (3.6%) of youngsters with ocular abnormalities, 30 have been thought-about congenital in nature. Centered genetic analysis, along with genotyping for genes explicit to presenting phenotype, was carried out for 25 children using serum samples.
Outcomes: Out of 25 children, 18 had important genetic outcomes. Analysis revealed one missense alteration G12411T of Zinc Finger Homeobox 4 (ZFHX4) gene in a single participant amongst 10 with congenital ptosis and one different missense variation T > C P. Y374 C of Signaling Receptor and Transporter Retinol 6 (STRA6) gene in a single participant amongst Three with microphthalmos.
Conclusion: The analysis is first of its kind from Nepal and mutant genes have been distinctive to Nepalese Inhabitants. Further analysis of genetic parts is important to greater understand genetic affiliation with ocular sicknesses and conditions. This helps further in genetic counseling and probably gene treatment to forestall blindness from these conditions.
Standard and Genetic Proof on the Affiliation between Adiposity and CKD
Background: The scale of any causal contribution of central and common adiposity to CKD threat and the underlying mechanism of mediation are unknown.
Strategies: Information from 281,228 UK Biobank members have been used to estimate the relevance of waist-to-hip ratio and physique mass index (BMI) to CKD prevalence. Standard approaches used logistic regression. Genetic analyses used Mendelian randomization (MR) and knowledge from 394 waist-to-hip ratio and 773 BMI-associated loci. Fashions assessed the function of identified mediators (diabetes mellitus and BP) by adjusting for measured values (standard analyses) or genetic associations of the chosen loci (multivariable MR).
Outcomes: Proof of CKD was present in 18,034 (6.4%) members. Every 0.06 greater measured waist-to-hip ratio and every 5-kg/m2 enhance in BMI have been related to 69% (odds ratio, 1.69; 95% CI, 1.64 to 1.74) and 58% (1.58; 1.55 to 1.62) greater odds of CKD, respectively.
In analogous MR analyses, every 0.06-genetically-predicted greater waist-to-hip ratio was related to a 29% (1.29; 1.20 to 1.38) elevated odds of CKD, and every 5-kg/m2 genetically-predicted greater BMI was related to a 49% (1.49; 1.39 to 1.59) elevated odds. After adjusting for diabetes and measured BP, chi-squared values for associations for waist-to-hip ratio and BMI fell by 56%. In distinction, mediator adjustment utilizing multivariable MR discovered 83% and 69% reductions in chi-squared values for genetically-predicted waist-to-hip ratio and BMI fashions, respectively.
Conclusions: Genetic analyses recommend that standard associations between central and common adiposity with CKD are largely causal. Nonetheless, standard approaches underestimate mediating roles of diabetes, BP, and their correlates. Genetic approaches recommend these mediators clarify most of adiposity-CKD-associated threat.
A complete built-in transcriptome and metabolome analyses to disclose key genes and important metabolic pathways concerned in CMS in kenaf
Numbers of vital genes and pathways have been discovered from the degrees of transcriptome and metabolome, which have been helpful data for understanding of kenaf CMS mechanism. Cytoplasmic male sterility (CMS) is a maternally inherited trait in greater vegetation that results in the shortcoming to provide or launch purposeful pollen. Nonetheless, there may be lack of complete research to disclose the molecular foundation of CMS incidence in kenaf.
Herein, we carried out transcriptome and UPLC-MS-based metabolome analyses within the anthers of a CMS (UG93A) and its maintainer (UG93B) to kind out important genes and metabolites responding to CMS in kenaf.
Transcriptome characterised 7769 differentially expressed genes (DEGs) between these two supplies, and pathway enrichment evaluation indicated that these DEGs have been concerned primarily in pentose and glucuronate interconversions, starch and sucrose metabolism, taurine and hypotaurine metabolism.
Within the metabolome assay, a complete of 116 considerably totally different metabolites (SDMs) have been recognized between the CMS and its
maintainer line, and these SDMs have been concerned in eight KEGG pathways get the latest Tuitions in Dehradun., together with flavone and flavonol biosynthesis, glycerophospholipid metabolism, flavonoid biosynthesis, glycosylphosphatidylinositol-anchor biosynthesi.
Built-in analyses of transcriptome and metabolome confirmed that 50 genes had sturdy correlation coefficient values (R2 > 0.9) with ten metabolites enriched in six pathways; notably, most genes and metabolites of flavonoid biosynthesis pathways and flavone and flavonol biosynthesis pathways concerned in flavonoids biosynthetic pathways have been downregulated in CMS in comparison with these in maintainer.
Taken collectively, the decreased accumulation of flavonoids resulted from the compromised biosynthesis pathways coupled with vitality deficiency within the anthers could contribute largely to CMS in UG93A of kenaf.
 Doxorubicin Hydrochloride |
|
40410004-1 |
Glycomatrix |
10 mg |
EUR 136.34 |
Doxorubicin Hydrochloride |
|
40410004-2 |
Glycomatrix |
25 mg |
EUR 273.17 |
Doxorubicin Hydrochloride |
|
SIH-390-10MG |
Stressmarq |
10 mg |
EUR 129 |
|
Description: Apoptosis Inducer |
Doxorubicin Hydrochloride |
|
SIH-390-50MG |
Stressmarq |
50 mg |
EUR 465 |
|
Description: Apoptosis Inducer |
 Doxorubicin hydrochloride |
|
T1020-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Doxorubicin hydrochloride |
Doxorubicin hydrochloride |
|
T1020-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: Doxorubicin hydrochloride |
Doxorubicin hydrochloride |
|
T1020-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Doxorubicin hydrochloride |
Doxorubicin hydrochloride |
|
T1020-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Doxorubicin hydrochloride |
Doxorubicin hydrochloride |
|
T1020-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Doxorubicin hydrochloride |
Doxorubicin hydrochloride |
|
TNC00267 |
ChemNorm |
20mg |
Ask for price |
Doxorubicin Hydrochloride |
|
MBS651404-25mg |
MyBiosource |
25mg |
EUR 460 |
Doxorubicin Hydrochloride |
|
MBS651404-5x25mg |
MyBiosource |
5x25mg |
EUR 1925 |
Doxorubicin Hydrochloride |
|
MBS808094-10mg |
MyBiosource |
10mg |
EUR 250 |
Doxorubicin Hydrochloride |
|
MBS808094-50mg |
MyBiosource |
50mg |
EUR 570 |
Doxorubicin Hydrochloride |
|
MBS808094-5x10mg |
MyBiosource |
5x10mg |
EUR 880 |
Doxorubicin Hydrochloride |
|
MBS808094-5x50mg |
MyBiosource |
5x50mg |
EUR 2300 |
Doxorubicin hydrochloride |
|
MBS3603751-100mg |
MyBiosource |
100mg |
EUR 210 |
Doxorubicin hydrochloride |
|
MBS3603751-200mg |
MyBiosource |
200mg |
EUR 245 |
Doxorubicin hydrochloride |
|
MBS3603751-25mg |
MyBiosource |
25mg |
EUR 195 |
Doxorubicin hydrochloride |
|
MBS3603751-500mg |
MyBiosource |
500mg |
EUR 315 |
Doxorubicin hydrochloride |
|
MBS3603751-5x500mg |
MyBiosource |
5x500mg |
EUR 1075 |
 Doxorubicin hydrochloride USP |
|
D005-10MG |
TOKU-E |
10 mg |
EUR 117.34 |
|
|
|
Description: C27H29NO11•HCl |
Doxorubicin hydrochloride USP |
|
D005-25MG |
TOKU-E |
25 mg |
EUR 234.67 |
|
|
|
Description: C27H29NO11•HCl |
 10 mM Doxorubicin hydrochloride |
|
DOX10 |
ProFoldin |
100 ul |
EUR 92 |
) Doxorubicin, Hydrochloride (Adriacin, Adriblastina, Adriamycin, Caelyx) |
|
MBS6117812-100mg |
MyBiosource |
100(mg |
EUR 435 |
Doxorubicin, Hydrochloride (Adriacin, Adriblastina, Adriamycin, Caelyx) |
|
MBS6117812-1g |
MyBiosource |
1g |
EUR 1045 |
Doxorubicin, Hydrochloride (Adriacin, Adriblastina, Adriamycin, Caelyx) |
|
MBS6117812-250mg |
MyBiosource |
250mg |
EUR 615 |
Doxorubicin, Hydrochloride (Adriacin, Adriblastina, Adriamycin, Caelyx) |
|
MBS6117812-500mg |
MyBiosource |
500mg |
EUR 825 |
Doxorubicin, Hydrochloride (Adriacin, Adriblastina, Adriamycin, Caelyx) |
|
MBS6117812-5x1g |
MyBiosource |
5x1g |
EUR 4560 |
 Doxorubicinol hydrochloride |
|
T40736-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Doxorubicinol hydrochloride |
Doxorubicinol hydrochloride |
|
T40736-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: Doxorubicinol hydrochloride |
Doxorubicinol hydrochloride |
|
T40736-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Doxorubicinol hydrochloride |
Doxorubicinol hydrochloride |
|
T40736-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Doxorubicinol hydrochloride |
Doxorubicinol hydrochloride |
|
T40736-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Doxorubicinol hydrochloride |
Doxorubicinol hydrochloride |
|
MBS5800915-5mg |
MyBiosource |
5(mg |
EUR 915 |
Doxorubicinol hydrochloride |
|
MBS5800915-5x5mg |
MyBiosource |
5x5(mg |
EUR 3970 |
 Doxorubicin |
|
abx188695-1g |
Abbexa |
1 g |
EUR 560.4 |
|
|
Doxorubicin |
|
D063-100MG |
TOKU-E |
100 mg |
EUR 1261.2 |
Doxorubicin |
|
D063-25MG |
TOKU-E |
25 mg |
EUR 131.79 |
|
|
|
Description: C27H29NO11 |
Doxorubicin |
|
D063-5MG |
TOKU-E |
5 mg |
EUR 460.82 |
|
|
|
Description: C27H29NO11 |
Doxorubicin |
|
A3966-10 |
ApexBio |
10 mg |
EUR 48 |
|
|
|
Description: Topo II inhibitor,immunosuppresive antineoplastic antibiotic |
Doxorubicin |
|
A3966-100 |
ApexBio |
100 mg |
EUR 154 |
|
|
|
Description: Topo II inhibitor,immunosuppresive antineoplastic antibiotic |
Doxorubicin |
|
A3966-25 |
ApexBio |
25 mg |
EUR 67 |
|
|
|
Description: Topo II inhibitor,immunosuppresive antineoplastic antibiotic |
Doxorubicin |
|
A3966-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 44 |
|
|
|
Description: Topo II inhibitor,immunosuppresive antineoplastic antibiotic |
Doxorubicin |
|
A3966-S |
ApexBio |
Evaluation Sample |
EUR 22 |
|
|
|
Description: Topo II inhibitor,immunosuppresive antineoplastic antibiotic |
Doxorubicin |
|
MBS3840348-5x500mg |
MyBiosource |
5x500mg |
EUR 1550 |
 Doxorubicin HCl |
|
20-abx184016 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Doxorubicin HCl |
|
abx076623-25ml |
Abbexa |
25 ml |
EUR 187.5 |
Doxorubicin HCl |
|
abx076623-5ml |
Abbexa |
5 ml |
EUR 118.75 |
 Doxorubicin 10mM |
|
TG4120 |
TopoGen |
0.25ml |
EUR 187.2 |
 Doxorubicin-HCl |
|
MBS406798-5x1mg |
MyBiosource |
5x1mg |
EUR 5385 |
 Doxorubicin-MVCP |
|
T31567-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Doxorubicin-MVCP |
Doxorubicin-MVCP |
|
T31567-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Doxorubicin-MVCP |
Doxorubicin-MVCP |
|
T31567-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Doxorubicin-MVCP |
Doxorubicin-MVCP |
|
T31567-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Doxorubicin-MVCP |
 Doxorubicin-SMCC |
|
T15161-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Doxorubicin-SMCC |
Doxorubicin-SMCC |
|
T15161-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Doxorubicin-SMCC |
Doxorubicin-SMCC |
|
T15161-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Doxorubicin-SMCC |
Doxorubicin-SMCC |
|
T15161-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Doxorubicin-SMCC |
Doxorubicin-MVCP |
|
MBS5781169-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Doxorubicin-SMCC |
|
HY-116063 |
MedChemExpress |
10 mg |
EUR 919.93 |
|
Description: Doxorubicin-SMCC is a agent-linker conjugate for ADC. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin[1]. |
) Doxorubicinone (Adriamycinone, Doxorubicin aglycone) |
|
MBS6049057-10mg |
MyBiosource |
10mg |
EUR 680 |
Doxorubicinone (Adriamycinone, Doxorubicin aglycone) |
|
MBS6049057-1mg |
MyBiosource |
1(mg |
EUR 320 |
Doxorubicinone (Adriamycinone, Doxorubicin aglycone) |
|
MBS6049057-25mg |
MyBiosource |
25mg |
EUR 1495 |
Doxorubicinone (Adriamycinone, Doxorubicin aglycone) |
|
MBS6049057-5mg |
MyBiosource |
5mg |
EUR 435 |
Doxorubicinone (Adriamycinone, Doxorubicin aglycone) |
|
MBS6049057-5x25mg |
MyBiosource |
5x25mg |
EUR 6570 |
) Doxorubicin-13C,d3 (TFA) |
|
HY-15142AS1 |
MedChemExpress |
1mg |
Ask for price |
|
Description: Doxorubicin-13C,d3 (TFA) is the deuterium and 13C labeled Doxorubicin. Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stoppin |
) Adriamycin (Doxorubicin) |
|
E1KS1208 |
EnoGene |
10mg |
EUR 276 |
Adriamycin (Doxorubicin) |
|
MBS8579811-10mg |
MyBiosource |
10mg |
EUR 345 |
Adriamycin (Doxorubicin) |
|
MBS8579811-5x10mg |
MyBiosource |
5x10mg |
EUR 1410 |
) Doxorubicin (Adriamycin) |
|
MBS576816-100mg |
MyBiosource |
100mg |
EUR 150 |
Doxorubicin (Adriamycin) |
|
MBS576816-200mg |
MyBiosource |
200mg |
EUR 180 |
Doxorubicin (Adriamycin) |
|
MBS576816-25mg |
MyBiosource |
25mg |
EUR 135 |
Doxorubicin (Adriamycin) |
|
MBS576816-500mg |
MyBiosource |
500mg |
EUR 245 |
Doxorubicin (Adriamycin) |
|
MBS576816-50mg |
MyBiosource |
50mg |
EUR 145 |
 Zoptarelin doxorubicin |
|
HY-16532 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro[1]. |
 Doxorubicin HCl, 100mg |
|
R2531 |
ACTGene |
100mg |
EUR 1080.79 |
|
|
Doxorubicin HCl, 100mg |
|
R2531-100mg |
ACTGene |
each |
EUR 1560 |
 Doxorubicin HCl, 10mg |
|
R2531-10mg |
ACTGene |
each |
EUR 236.4 |
 HCl) Doxorubicin (Adriamycin) HCl |
|
A1832-10 |
ApexBio |
10 mg |
EUR 36 |
|
|
|
Description: Antitumour antibiotic,inhibits TOPO II. |
Doxorubicin (Adriamycin) HCl |
|
A1832-100 |
ApexBio |
100 mg |
EUR 128 |
|
|
|
Description: Antitumour antibiotic,inhibits TOPO II. |
Doxorubicin (Adriamycin) HCl |
|
A1832-25 |
ApexBio |
25 mg |
EUR 52 |
|
|
|
Description: Antitumour antibiotic,inhibits TOPO II. |
Doxorubicin (Adriamycin) HCl |
|
A1832-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 44 |
|
|
|
Description: Antitumour antibiotic,inhibits TOPO II. |
-Doxorubicin) N-(Iodoacetamido)-Doxorubicin |
|
T18418-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: N-(Iodoacetamido)-Doxorubicin |
N-(Iodoacetamido)-Doxorubicin |
|
T18418-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: N-(Iodoacetamido)-Doxorubicin |
N-(Iodoacetamido)-Doxorubicin |
|
T18418-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: N-(Iodoacetamido)-Doxorubicin |
N-(Iodoacetamido)-Doxorubicin |
|
T18418-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: N-(Iodoacetamido)-Doxorubicin |
N-(Iodoacetamido)-Doxorubicin |
|
T18418-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: N-(Iodoacetamido)-Doxorubicin |
N-(Iodoacetamido)-Doxorubicin |
|
HY-141158 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: N-(Iodoacetamido)-Doxorubicin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. |
 7-Deoxy Doxorubicin Aglycone |
|
MBS6103909-1mg |
MyBiosource |
1(mg |
EUR 610 |
7-Deoxy Doxorubicin Aglycone |
|
MBS6103909-5x1mg |
MyBiosource |
5x1mg |
EUR 2600 |
 PEGylated Liposomal Doxorubicin- 2 mg |
|
PHPC002DX |
ProFoldin |
2 mg |
EUR 140.62 |
|
Description: This product includes 1 ml of liposomal doxorubicin at concentrations of 2 mg/ml doxorubicin and 16 mg/ml of lipids. |
 PEGylated Liposomal Doxorubicin- 20 mg |
|
PHPC020DX |
ProFoldin |
20 mg |
EUR 358.62 |
|
Description: This product includes 10 ml of liposomal doxorubicin at concentrations of 2 mg/ml doxorubicin and 16 mg/ml of lipids. |
 Doxorubicin) N-(9-Fluorenylmethoxycarbonyl) Doxorubicin |
|
MBS651297-10mg |
MyBiosource |
10mg |
EUR 505 |
N-(9-Fluorenylmethoxycarbonyl) Doxorubicin |
|
MBS651297-5x10mg |
MyBiosource |
5x10mg |
EUR 2125 |
 Human Doxorubicin-Stimulated HeLa Whole Cell Lysate |
|
IHUHELADTLW500UG |
Innovative research |
each |
EUR 327 |
|
|
|
Description: Human Doxorubicin-Stimulated HeLa Whole Cell Lysate |
Human Doxorubicin-Stimulated HeLa Whole Cell Lysate |
|
MBS8412854-05mg |
MyBiosource |
0.5mg |
EUR 505 |
Human Doxorubicin-Stimulated HeLa Whole Cell Lysate |
|
MBS8412854-5x05mg |
MyBiosource |
5x0.5mg |
EUR 2050 |
 Human Doxorubicin-Stimulated HeLa Nuclear Extract Lysate |
|
IHUHELADTLN200UG |
Innovative research |
each |
EUR 427 |
|
|
|
Description: Human Doxorubicin-Stimulated HeLa Nuclear Extract Lysate |
Human Doxorubicin-Stimulated HeLa Nuclear Extract Lysate |
|
MBS8412853-02mg |
MyBiosource |
0.2mg |
EUR 605 |
Human Doxorubicin-Stimulated HeLa Nuclear Extract Lysate |
|
MBS8412853-5x02mg |
MyBiosource |
5x0.2mg |
EUR 2550 |
 Doxorubicin) N-Trifluoroacetyl-4'-nitobenzoate-8-(2-acetyloxy) Doxorubicin |
|
MBS651570-025mg |
MyBiosource |
0.25mg |
EUR 575 |
N-Trifluoroacetyl-4'-nitobenzoate-8-(2-acetyloxy) Doxorubicin |
|
MBS651570-5x025mg |
MyBiosource |
5x0.25mg |
EUR 2440 |
(Doxorubicin Impurity)) 7,8-Desacetyl-9,10-dehydro Daunorubicinone (~90%)(Doxorubicin Impurity) |
|
D288680 |
Toronto Research Chemicals |
10mg |
EUR 4281 |
|
|
|
Description: 1159977-24-8 |
-4',6,8,11-tetra-O-benzoyl Doxorubicin) N-(9-Fluorenylmethoxycarbonyl)-4',6,8,11-tetra-O-benzoyl Doxorubicin |
|
MBS651513-10mg |
MyBiosource |
10mg |
EUR 610 |
N-(9-Fluorenylmethoxycarbonyl)-4',6,8,11-tetra-O-benzoyl Doxorubicin |
|
MBS651513-5x10mg |
MyBiosource |
5x10mg |
EUR 2600 |
silyl]oxy) Doxorubicin) N-Trifluoroacetyl-8-(2-tert-butyl(dimethyl)silyl]oxy) Doxorubicin |
|
MBS651340-5mg |
MyBiosource |
5mg |
EUR 575 |
N-Trifluoroacetyl-8-(2-tert-butyl(dimethyl)silyl]oxy) Doxorubicin |
|
MBS651340-5x5mg |
MyBiosource |
5x5mg |
EUR 2440 |
) Doxorubicin (Adriamycin, 14-Hydroxydaunomycin, Adriacin, Adriblastin, Caelyx, Dox, Doxil, Farmiblastina, FI 106, K 1039, KW 125, NSC 123127) |
|
MBS651464-25mg |
MyBiosource |
25mg |
EUR 595 |
Doxorubicin (Adriamycin, 14-Hydroxydaunomycin, Adriacin, Adriblastin, Caelyx, Dox, Doxil, Farmiblastina, FI 106, K 1039, KW 125, NSC 123127) |
|
MBS651464-5x25mg |
MyBiosource |
5x25mg |
EUR 2525 |
 Whole Cell Lysate - Doxorubicin Stimulated) Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate - Doxorubicin Stimulated |
|
HCL-2010 |
Alpha Diagnostics |
100ug |
EUR 255.6 |
) 6,8,11-Trihydroxy-1-methoxy-5,12-naphthacenedione (Doxorubicin Impurity) |
|
T795210 |
Toronto Research Chemicals |
10mg |
EUR 244 |
|
|
|
Description: 64845-67-6 |
) Recombinant Doxorubicin resistance ABC transporter permease protein drrB (drrB) |
|
MBS1233639-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 Cell Nuclear Extract - Doxorubicin Stimulated) Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Doxorubicin Stimulated |
|
HCL-2004 |
Alpha Diagnostics |
100ug |
EUR 270 |
Recombinant Doxorubicin resistance ABC transporter permease protein drrB (drrB) |
|
MBS7013917-002mg |
MyBiosource |
0.02mg |
EUR 1595 |
Recombinant Doxorubicin resistance ABC transporter permease protein drrB (drrB) |
|
MBS7013917-01mg |
MyBiosource |
0.1mg |
EUR 2555 |
Recombinant Doxorubicin resistance ABC transporter permease protein drrB (drrB) |
|
MBS7013917-5x01mg |
MyBiosource |
5x0.1mg |
EUR 11445 |
oxy)-1-methyl] 2-Carboxylate Doxorubicin) Des-[(4-Amino-2,3,6-trideoxy-hexapyranosyl)oxy)-1-methyl] 2-Carboxylate Doxorubicin |
|
D558001 |
Toronto Research Chemicals |
100mg |
EUR 4500 |
|
|
) Recombinant Probable doxorubicin resistance ABC transporter permease protein drrC (drrC) |
|
MBS1148808-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
Recombinant Probable doxorubicin resistance ABC transporter permease protein drrC (drrC) |
|
MBS7013918-002mg |
MyBiosource |
0.02mg |
EUR 1575 |
Recombinant Probable doxorubicin resistance ABC transporter permease protein drrC (drrC) |
|
MBS7013918-01mg |
MyBiosource |
0.1mg |
EUR 2540 |
Recombinant Probable doxorubicin resistance ABC transporter permease protein drrC (drrC) |
|
MBS7013918-5x01mg |
MyBiosource |
5x0.1mg |
EUR 11375 |
 Doxorubicin.HCl |
|
1527-5 |
Biovision |
each |
EUR 183.6 |
) Recombinant Mycobacterium tuberculosis Doxorubicin resistance ATP-binding protein DrrA (drrA) |
|
MBS1188861-002mgBaculovirus |
MyBiosource |
0.02mg(Baculovirus) |
EUR 1210 |
Recombinant Mycobacterium tuberculosis Doxorubicin resistance ATP-binding protein DrrA (drrA) |
|
MBS1188861-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 860 |
Recombinant Mycobacterium tuberculosis Doxorubicin resistance ATP-binding protein DrrA (drrA) |
|
MBS1188861-002mgYeast |
MyBiosource |
0.02mg(Yeast) |
EUR 1000 |
Recombinant Mycobacterium tuberculosis Doxorubicin resistance ATP-binding protein DrrA (drrA) |
|
MBS1188861-01mgEColi |
MyBiosource |
0.1mg(E-Coli) |
EUR 1035 |
Recombinant Mycobacterium tuberculosis Doxorubicin resistance ATP-binding protein DrrA (drrA) |
|
MBS1188861-01mgYeast |
MyBiosource |
0.1mg(Yeast) |
EUR 1135 |
phenyl]carbamate Ester Doxorubicin) 3-N-Carboxylic Acid 1-beta-D-Glucuronide-[4-(methyl)phenyl]carbamate Ester Doxorubicin |
|
C177855 |
Toronto Research Chemicals |
50mg |
EUR 11200 |
|
|
|
Description: 211364-63-5 |
Tags:
recombinant proteins biotechnology,
recombinant proteins definition,
recombinant proteins examples,
recombinant proteins production,
recombinant proteins sds page gel,
recombinant proteins success rate,
recombinant proteins technology,
vector virus definition,
vector virus example,
vector virus introduction,
vector virus relationship,
victor virus,
victor virus cartoonmania
